German pharmaceuticals and agriculture group Bayer on Tuesday raised its 2026 profit outlook, citing stronger-than-expected performance in its pharmaceuticals business, which delivered sales above market estimates in the third quarter, Reuters reported.
The company now expects adjusted core earnings, on a currency-adjusted basis, to reach between 9.8 billion euros and 10.3 billion euros in 2026. This compares with its previous forecast of 9.6 billion euros to 10.1 billion euros.